Novartis launches Radioligand Therapy for advanced prostate cancer treatment in India
June 15, 2026 | Monday | News
Brings a globally recognised targeted treatment approach to Indian patients
In a major advancement for cancer care in India, Novartis India has announced the launch of Pluvicto (lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority approved radioligand therapy for eligible patients with Prostate-Specific Membrane Antigen (PSMA)-positive prostate cancer.
Designed to precisely target prostate cancer cells while minimising exposure to healthy tissues, Pluvicto introduces a new treatment approach for metastatic prostate cancer, a disease that continues to place a significant physical and emotional burden on patients and families across India.
Pluvicto is the only regulatory authority approved finished formulation for PSMA +metastatic castration resistant prostate cancer (mCRPC) and is imported from Spain and Italy from GMP facilities, ensuring the highest standards of quality and safety.
The launch comes at a time when prostate cancer is emerging as one of India’s fastest-growing cancer burdens among men. Prostate cancer is now among the top three cancers affecting urban men in India, with nearly 250,000 cases every year. Approximately 50% of diagnosed patients present at a metastatic stage, where treatment becomes significantly more complex due to poorer prognosis, treatment-related side effects, and challenges in treatment sequencing.
Pluvicto will be made available through select hospitals and nuclear medicine centres across India as part of Novartis’ partnership-led approach for bringing radioligand therapies to India. The company is also working with healthcare stakeholders to strengthen awareness, and infrastructure preparedness for precision oncology care.